利福平耐药结核病患者不良治疗结局及其影响因素研究进展  

Research progress on unfavourable treatment outcomes and risk factors of rifampicin-resistant tuberculosis patients

作　　者：孙慧娟 苏伟[1] 陈伟[1] Sun Huijuan;Su Wei;Chen Wei(National Center for Tuberculosis Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China)

机构地区：[1]中国疾病预防控制中心结核病预防控制中心,北京102206

出　　处：《结核与肺部疾病杂志》2024年第6期573-582,共10页Journal of Tuberculosis and Lung Disease

基　　金：中央财政结核病预防控制项目(2428)。

摘　　要：近年来,耐药结核病的流行和传播给全球结核病控制带来了巨大的挑战,尤其是利福平耐药结核病,因其治疗周期长、治疗难度大、治疗费高、不良反应多等原因易出现中断治疗、治疗失败、失访等不良结局,严重影响患者治疗效果和生存质量。作者系统介绍了国内外利福平耐药结核病患者不良治疗结局的发生情况,探讨利福平耐药结核病不良治疗结局的影响因素,为制定提高利福平耐药结核病患者治疗效果的防治策略提供参考依据。In recent years,the prevalence and transmission of drug-resistant tuberculosis has posed significant challenges to global tuberculosis control,particularly rifampicin-resistant tuberculosis.This form of the disease is characterized by long treatment duration,difficulty in management,high costs,and numerous adverse reactions,which often lead to unfavorable treatment outcomes such as treatment interruption,treatment failure,and loss to follow-up,severely affecting treatment outcomes and quality of life.The authors systematically present the occurrence of adverse treatment outcomes among patients with rifampicin-resistant tuberculosis patients both domestically and internationally,and discusses the factors that influence these unfavorable outcomes,thereby providing a reference for the development of preventive and therapeutic strategies aimed at improving the treatment effectiveness of rifampicin-resistant tuberculosis patients.

关 键 词：结核 利福平 抗多种药物性 治疗结果 危险因素 统计学 

分 类 号：R521[医药卫生—内科学]